CHM chimeric therapeutics limited

0.00%

0.4¢

Actually nice to see some discussion instead of watching tumble...

First 105 Last

Share
Profile

Follow
Paulfool

1,273 Posts.

739

08/09/22

00:14

Post #: 63576569
Share

Originally posted by Danielguda1: ↑

I wasn't replying to you, i was more replying to the other comments but accidentally deleted the reply tag. [Replying to speccys more recent post...it keeps on deleting the reply tag]

I think when I say that, I do not assume the success of each drug. If you put where both drugs are at:
- Both haven't started Phase 1
- Both are in the IND stage (Century got theirs approved last week and CHM will be expecting it early next year or late this year).
- Both are speculative

I think they are quite comparable in terms of their stage in the development process and if I was to pick one. I would choose the one with the more advanced tech.

Also, I've not invested in either Nkarta or Century Therapeutics. I'm waiting for prices to go down lower, biotechs do not do well in high-interest rate environments. But I merely brought them up to say that there might be better programs out there other than CHM

The main basis of my divestment in the company is their CLTX CAR-T. I see too many red flags for it to produce results that will change market sentiment. Maybe I'm wrong and these series of posts could make me look like a dud but there are too many unknowns to ride when you either could:
- Buy at even lower prices on a negative result of CLTX CAR-T
- Buy 50% higher than the price on a positive result of CLTX CAR-T with more clarity on how the product works.

Again just a risk management play.

Expand

Actually nice to see some discussion instead of watching tumble weeds while waiting for trial updates.

With all the collaborations I would think that at least a 2nd site would be up and running by now.

Looking forward to CDH17 news though.

CHM Price at posting: 10.0¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

First 105 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $8.060M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$19.57K	4.893M

Buyers (Bids)

No.	Vol.	Price($)
4	419507	0.4¢

Sellers (Offers)

Price($)	Vol.	No.
0.5¢	18587873	22

View Market Depth

No.	Vol.	Price($)
4	419507	0.004
39	26659272	0.003
15	14700506	0.002
12	54600000	0.001
0	0	0.000

Price($)	Vol.	No.
0.005	17587873	20
0.006	13115184	13
0.007	3100000	2
0.008	8542434	6
0.009	2390797	5

Last trade - 15.59pm 27/06/2025 (20 minute delay)

CHM (ASX) Chart

Actually nice to see some discussion instead of watching tumble...

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Monash IVF shares cater 25% – Disaster or deep-value play?

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Actually nice to see some discussion instead of watching tumble...

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Monash IVF shares cater 25% – Disaster or deep-value play?

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News